Formycon AG (XETRA:FYB) — Market Cap & Net Worth
Market Cap & Net Worth: Formycon AG (FYB)
Formycon AG (XETRA:FYB) has a market capitalization of $338.61 Million (€289.63 Million) as of September 18, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #14358 globally and #1440 in its home market, demonstrating a -2.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Formycon AG's stock price €19.80 by its total outstanding shares 17672927 (17.67 Million). Also see FYB current and non-current assets for a full breakdown of the balance sheet.
Formycon AG Market Cap History: 2015 to 2026
Formycon AG's market capitalization history from 2015 to 2026. Data shows change from $491.02 Million to $409.10 Million (-1.44% CAGR). Also see Formycon AG cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Formycon AG is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
HDAX Price
GDAXHIP
|
$1.40 Trillion | 0.02% | #65 of 102 |
Weight: Formycon AG's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Formycon AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Formycon AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Formycon AG stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
11.89x
Formycon AG's market cap is 11.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $493.60 Million | $19.53 Million | -$4.07 Million | 25.27x | N/A |
| 2017 | $675.53 Million | $29.00 Million | -$1.58 Million | 23.29x | N/A |
| 2018 | $537.20 Million | $42.99 Million | $7.10 Million | 12.49x | 75.68x |
| 2019 | $659.10 Million | $33.16 Million | -$2.29 Million | 19.88x | N/A |
| 2020 | $1.10 Billion | $34.23 Million | -$6.73 Million | 31.99x | N/A |
| 2021 | $1.22 Billion | $36.61 Million | -$13.29 Million | 33.29x | N/A |
| 2022 | $1.79 Billion | $42.50 Million | $35.99 Million | 42.06x | 49.66x |
| 2023 | $1.17 Billion | $77.70 Million | $75.80 Million | 15.00x | 15.37x |
| 2024 | $1.10 Billion | $69.67 Million | -$125.67 Million | 15.75x | N/A |
| 2025 | $528.93 Million | $44.48 Million | -$64.70 Million | 11.89x | N/A |
Competitor Companies of FYB by Market Capitalization
Companies near Formycon AG in the global market cap rankings as of September 18, 2026. Review FYB goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Formycon AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Formycon AG Historical Marketcap From 2015 to 2026
Between 2015 and today, Formycon AG's market cap moved from $491.02 Million to $ 409.10 Million, with a yearly change of -1.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €409.10 Million | -22.66% |
| 2025 | €528.93 Million | -51.79% |
| 2024 | €1.10 Billion | -5.85% |
| 2023 | €1.17 Billion | -34.80% |
| 2022 | €1.79 Billion | +46.61% |
| 2021 | €1.22 Billion | +11.32% |
| 2020 | €1.10 Billion | +66.14% |
| 2019 | €659.10 Million | +22.69% |
| 2018 | €537.20 Million | -20.48% |
| 2017 | €675.53 Million | +36.86% |
| 2016 | €493.60 Million | +0.53% |
| 2015 | €491.02 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Formycon AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $338.61 Million USD |
| MoneyControl | $338.61 Million USD |
| MarketWatch | $338.61 Million USD |
| marketcap.company | $338.61 Million USD |
| Reuters | $338.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more